Table 4.

Adverse events and frequency (occurring in ≥30%) (left panel) and ≥grade 3 adverse events and frequency (occurring in ≥10%) (right panel) of 526 patients enrolled in PX-171-003- A0, PX-171-003-A1, PX-171-004, and PX-171-005 trials

Adverse event	Frequency (%)	≥grade 3 adverse event	Frequency (%)
Fatigue	55	Thrombocytopenia	23
Anemia	47	Anemia	22
Nausea	42	Lymphopenia	18
Thrombocytopenia	36	Pneumonia	11
Dyspnea	35	Neutropenia	10
Diarrhea	33
Pyrexia	30